Focus: Cancer Center Featured Story 2

Filters close
Released: 28-Sep-2016 10:05 AM EDT
Nanoparticle Creates ‘Wave of Destruction’ in Cancer Cells
Cornell University

Nanoparticles known as Cornell dots, or C dots, have shown great promise as a therapeutic tool in the detection and treatment of cancer. Now, the ultrasmall particles have shown they can do something even better: kill cancer cells without attaching a cytotoxic drug.

Released: 27-Sep-2016 3:05 PM EDT
Mastectomy Plus Reconstruction Has Highest Rate of Complication, Complication-Related Costs of Guideline-Concordant Therapies for Early Breast Cancer
University of Texas MD Anderson Cancer Center

In a review of guideline-concordant treatment modalities for women with early stage breast cancer, mastectomy and reconstruction had the highest rate of complications and complication-related costs, regardless of age.

Released: 27-Sep-2016 3:05 PM EDT
Tackling Obesity in Rural Communities
University of Kansas Cancer Center

Currently, excess body weight contributes to as many as 1 in 5 cancer-related deaths. Obesity is associated with increased risk of at least eight types of cancer. The American Society of Clinical Oncology has identified obesity as a health risk that is “quickly overtaking tobacco as the leading preventable cause of cancer.”

Released: 27-Sep-2016 2:05 PM EDT
Seattle Cancer Care Alliance Opens Prostate Cancer Genetics Specialty Clinic
Seattle Cancer Care Alliance

Seattle Cancer Care Alliance (SCCA) has opened a new Prostate Cancer Genetics Clinic at their South Lake Union campus in Seattle. The specialty clinic will serve patients with prostate cancer that has spread beyond the prostate (metastatic) and/or who have a family history of the disease or a family history of breast cancer, ovarian cancer, pancreatic cancer, lymphoma or leukemia. These men are more likely to have an inherited and more aggressive form of prostate cancer. Knowing a patient has a particular genetic mutation helps doctors choose the best treatment plan and can open doors for innovative clinical trials.

Released: 27-Sep-2016 1:05 PM EDT
Radiation Boost Reduces Local Tumor Recurrence for DCIS Patients Following WBRT
Yale Cancer Center/Smilow Cancer Hospital

A supplemental “boost” of radiation improves local control and provides an incremental benefit in decreasing breast cancer recurrence for patients with Ductal Carcinoma In Situ (DCIS) who receive whole breast radiation therapy radiation (WBRT) following lumpectomy, according to research presented today at the 58th Annual Meeting of the American Society for Radiation Oncology (ASTRO).

Released: 27-Sep-2016 12:05 PM EDT
Optimal Management for NSCLC Patients with Brain Metastases
Yale Cancer Center/Smilow Cancer Hospital

A Yale Cancer Center team completed a multi-institutional analysis of treatment options for patients with newly diagnosed EGFR-mutant non-small cell lung cancer (NSCLC) with brain metastases to determine the best option for treatment.

Released: 27-Sep-2016 12:05 PM EDT
Link Between Facility Volume and Radiation Outcomes for Head and Neck Cancers
Yale Cancer Center/Smilow Cancer Hospital

The association between provider case volume and outcomes has long been suggested in cancer care. A Yale Cancer Center team has completed a review of outcomes for patients with locally advanced squamous cell head and neck cancers treated with intensity-modulated radiation therapy (IMRT) and found a distinct association between higher-volume treatment centers and improved overall survival.

Released: 27-Sep-2016 10:05 AM EDT
For Some Lung Cancer Patients Receiving SBRT, One and Done Approach Works Best
Roswell Park Comprehensive Cancer Center

A new study led by Anurag Singh, MD, of Roswell Park Cancer Institute and presented at the American Society for Radiation Oncology (ASTRO) 2016 Annual Meeting suggests that a single high-intensity SBRT dose can be as effective as three slightly lower doses of radiation.

Released: 27-Sep-2016 9:05 AM EDT
Taking Aim at Triple-Negative Breast Cancer
Rutgers Cancer Institute

Rutgers Cancer Institute of New Jersey researchers in the Precision Medicine Program aim to validate a new genomic sequencing approach that may help identify a sub-set of triple-negative breast cancers. The work is supported by a grant from the Val Skinner Foundation.

Released: 27-Sep-2016 7:05 AM EDT
HERO Event Celebrates People Who Take Part in Cancer Clinical Research
University of New Mexico Comprehensive Cancer Center

The ninth annual Helping to Enhance Research in Oncology event will honor those who take part in cancer clinical trials. The event will also raise awareness for the importance of cancer clinical trials and will offer education sessions about clinical trials that are free and open to the public. The New Mexico Cancer Care Alliance is sponsoring the event.

Released: 26-Sep-2016 11:55 AM EDT
NCCN Publishes New Clinical Practice Guidelines for Myeloproliferative Neoplasms
National Comprehensive Cancer Network® (NCCN®)

New NCCN Guidelines for Myeloproliferative Neoplasms focus on the treatment of Myelofibrosis, a rare bone marrow cancer; the new recommendations are the most comprehensive treatment guidance available to U.S. clinicians today.

Released: 26-Sep-2016 10:05 AM EDT
Radiation Therapy and Radical Prostatectomy Further Explored for Initial Diagnosis of Advanced Prostate Cancer
Rutgers Cancer Institute

A database study examining surgical removal of the prostate gland (radical prostatectomy) or a form of radiation therapy known as IMRT to treat prostate cancer that has spread to other parts of the body (metastatic) shows an association between each of these treatments and improved overall survival.

Released: 26-Sep-2016 10:05 AM EDT
Medulloblastoma Patients Should Receive Both Chemotherapy and Radiation Post-Surgery
Yale Cancer Center/Smilow Cancer Hospital

In a recent study, a Yale Cancer Center team revealed that the addition of chemotherapy to postoperative treatment for adults with medulloblastoma improves survival.

26-Sep-2016 6:30 AM EDT
MD Anderson Cancer Center and Adaptimmune Form Strategic Alliance to Advance Development of Immunotherapies Targeting Multiple Cancers
University of Texas MD Anderson Cancer Center

Adaptimmune Therapeutics and The University of Texas MD Anderson Cancer Center announced today they have entered into a multi-year strategic alliance designed to expedite the development of novel adoptive T-cell therapies for multiple types of cancer.

Released: 23-Sep-2016 2:05 PM EDT
Pembrolizumab Approval Is Tip of the Iceberg for Immunotherapy in HNSCC
Yale Cancer Center/Smilow Cancer Hospital

Immunotherapy is a big change for head and neck cancer and there seems to be no doubt that there is activity for immunotherapies with pembrolizumab as well as nivolumab [Opdivo]” said Burtness, professor of Medicine at Yale Cancer Center.

Released: 23-Sep-2016 1:05 PM EDT
Yale Team Compares Effectiveness of Four PD-L1 Tests
Yale Cancer Center/Smilow Cancer Hospital

In a recent study, a Yale Cancer Center team compared the performance of the four available PD-L1 assay tests. They found that one of the assays failed to reveal comparable levels of PD-L1, a tumor-promoting protein, while three others revealed comparable levels.

Released: 23-Sep-2016 12:05 PM EDT
‘Cellbots’ Chase Down Cancer, Deliver Drugs Directly to Tumors
UCSF Helen Diller Family Comprehensive Cancer Center

UC San Francisco scientists have engineered human immune cells that can precisely locate diseased cells anywhere in the body and execute a wide range of customizable responses, including the delivery of drugs or other therapeutic payloads directly to tumors or other unhealthy tissues. In experiments with mice, these immune cells, called synNotch T cells, efficiently homed in on tumors and released a specialized antibody therapy, eradicating the cancer without attacking normal cells.

Released: 22-Sep-2016 5:05 PM EDT
Fred Hutch Researchers Jesse Bloom and Frederick Matsen Selected as Howard Hughes Medical Institute Faculty Scholars
Fred Hutchinson Cancer Center

Drs. Jesse Bloom and Frederick “Erick” Matsen, evolutionary researchers at Fred Hutchinson Cancer Research Center, were named Faculty Scholars today by the Howard Hughes Medical Institute and the Simons Foundation. This honor comes with five years of unrestricted philanthropic support for these two scientists, both of whom focus on developing methods for understanding evolution, especially the evolution of pathogens and immune resistance.

Released: 5-Nov-2013 3:00 PM EST
Duke Cancer Institute
NCI-Designated Cancer Centers

Among the research institutions the National Cancer Institute funds across the United States, it currently designates 68 as Cancer Centers. Largely based in research universities, these facilities are home to many of the NCI-supported scientists who conduct a wide range of intense, laboratory research into cancer’s origins and development. This profile provides some history of the Duke Cancer Institute as well as a look at its current initiatives.

Released: 4-Sep-2013 4:05 PM EDT
Wear Your Vegetables
NCI-Designated Cancer Centers

With skin cancer emerging as one of the world’s most prevalent forms of cancer, researchers are using every tool at their disposal to fight this disease. The tool of choice for Sally Dickinson, PhD? Broccoli.

Released: 20-Aug-2013 10:00 AM EDT
Dana-Farber/ Harvard Cancer Center
NCI-Designated Cancer Centers

Among the research institutions the National Cancer Institute funds across the United States, it currently designates 68 as Cancer Centers. Largely based in research universities, these facilities are home to many of the NCI-supported scientists who conduct a wide range of intense, laboratory research into cancer’s origins and development. This profile provides some history of the Dana-Farber/Harvard Cancer Center as well as a look at its current initiatives.

Released: 30-Jul-2013 11:55 AM EDT
City of Hope Comprehensive Cancer Center
NCI-Designated Cancer Centers

Among the research institutions the National Cancer Institute funds across the United States, it currently designates 68 as Cancer Centers. Largely based in research universities, these facilities are home to many of the NCI-supported scientists who conduct a wide range of intense, laboratory research into cancer’s origins and development. This profile provides some history of the City of Hope Comprehensive Cancer Center as well as a look at its current initiatives.

Released: 23-Jul-2013 11:00 AM EDT
University of New Mexico Cancer Center
NCI-Designated Cancer Centers

Among the research institutions the National Cancer Institute funds across the United States, it currently designates 68 as Cancer Centers. Largely based in research universities, these facilities are home to many of the NCI-supported scientists who conduct a wide range of intense, laboratory research into cancer’s origins and development. This profile provides some history of the University of New Mexico Cancer Center as well as a look at its current initiatives.

Released: 12-Jul-2013 1:15 PM EDT
Cancer Therapy & Research Center
NCI-Designated Cancer Centers

Among the research institutions the National Cancer Institute funds across the United States, it currently designates 68 as Cancer Centers. Largely based in research universities, these facilities are home to many of the NCI-supported scientists who conduct a wide range of intense, laboratory research into cancer’s origins and development. This profile provides some history of the Cancer Therapy & Research Center as well as a look at its current initiatives.

Released: 1-Jul-2013 2:25 PM EDT
Rutgers Cancer Institute of New Jersey
NCI-Designated Cancer Centers

Among the research institutions the National Cancer Institute funds across the United States, it currently designates 68 as Cancer Centers. Largely based in research universities, these facilities are home to many of the NCI-supported scientists who conduct a wide range of intense, laboratory research into cancer’s origins and development. This profile provides some history of the Rutgers Cancer Institute of New Jersey as well as a look at its current initiatives.

Released: 21-Jun-2013 1:55 PM EDT
Siteman Cancer Center
NCI-Designated Cancer Centers

Among the research institutions the National Cancer Institute funds across the United States, it currently designates 68 as Cancer Centers. Largely based in research universities, these facilities are home to many of the NCI-supported scientists who conduct a wide range of intense, laboratory research into cancer’s origins and development. This profile provides some history of the Siteman Cancer Center as well as a look at its current initiatives.

Released: 11-Jun-2013 9:00 AM EDT
Albert Einstein Cancer Institute
NCI-Designated Cancer Centers

Among the research institutions the National Cancer Institute funds across the United States, it currently designates 68 as Cancer Centers. Largely based in research universities, these facilities are home to many of the NCI-supported scientists who conduct a wide range of intense, laboratory research into cancer’s origins and development. This profile provides some history of the Albert Einstein Cancer Center as well as a look at its current initiatives.

Released: 4-Jun-2013 12:50 PM EDT
Abramson Cancer Center of the University of Pennsylvania
NCI-Designated Cancer Centers

Among the research institutions the National Cancer Institute funds across the United States, it currently designates 68 as Cancer Centers. Largely based in research universities, these facilities are home to many of the NCI-supported scientists who conduct a wide range of intense, laboratory research into cancer’s origins and development. This profile provides some history of Abramson Cancer Center as well as a look at its current initiatives.



close
8.30409